Biofrontera Inc
$ 1.27
1.60%
07 Aug - close price
- Market Cap 16,260,200 USD
- Current Price $ 1.27
- High / Low $ 1.27 / 1.23
- Stock P/E N/A
- Book Value 0.51
- EPS -0.99
- Next Earning Report 2026-08-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.32 %
- ROE -3.39 %
- 52 Week High 1.27
- 52 Week Low 0.56
About
Biofrontera Inc., a biopharmaceutical company, develops and supplies dermatological products for the treatment of skin conditions in the United States. The company is headquartered in Woburn, Massachusetts.
Analyst Target Price
$5.88
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-14 | 2026-03-19 | 2025-11-12 | 2025-08-13 | 2025-05-15 | 2025-03-21 | 2024-11-13 | 2024-08-14 | 2024-05-15 | 2024-03-15 | 2023-11-09 | 2023-08-11 |
| Reported EPS | -0.41 | 0.5 | -0.57 | -0.57 | -0.47 | -0.232 | -0.81 | -1.08 | -2.88 | -0.68 | -3.16 | -6.07 |
| Estimated EPS | -0.05 | 0.1 | -0.56 | -0.39 | -0.14 | -0.07 | -0.94 | -0.35 | -1.17 | -0.85 | -3.34 | -4.08 |
| Surprise | -0.36 | 0.4 | -0.01 | -0.18 | -0.33 | -0.162 | 0.13 | -0.73 | -1.71 | 0.17 | 0.18 | -1.99 |
| Surprise Percentage | -720% | 400% | -1.7857% | -46.1538% | -235.7143% | -231.4286% | 13.8298% | -208.5714% | -146.1538% | 20% | 5.3892% | -48.7745% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-13 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.17 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BFRI
2026-08-06 11:11:10
Biofrontera Inc. (BFRI) is scheduled to release its Q2'26 earnings on August 7th. Analysts estimate the company will report revenue of $9.50 million and an earnings per share (EPS) of ($0.10) for the quarter. The article also provides historical reported and estimated revenue and EPS figures for previous quarters.
2026-08-05 22:04:27
Biofrontera Inc. (NASDAQ: BFRI) announced it will report its second-quarter 2026 financial results on Thursday, August 13, 2026, before market open. Management will host a conference call and webcast at 10:00 a.m. Eastern Time on the same day to discuss the results and provide a business update. Investors can join via a toll-free number or a webcast link.
2026-08-05 20:04:27
Biofrontera Inc. (NASDAQ: BFRI), a U.S. specialty dermatology company, announced it will report its second-quarter 2026 financial results on Thursday, August 13, 2026, before the market opens. Following the release, management will host a conference call and webcast at 10:00 a.m. Eastern Time to discuss the results and provide a business update. The company specializes in commercializing Ameluz® with the BF-RhodoLED® lamp for photodynamic therapy of actinic keratosis.
2026-07-31 09:10:03
The article provides an analysis of Biofrontera Inc's financial health, indicating a stable financial status and high operating efficiency with a current financial score of 8.06. It highlights the company's latest quarterly revenue of $10.08 million, showing a 17.42% year-over-year increase, and a 13.06% year-over-year increase in net profit. The company ranks 75 out of 155 in the Pharmaceuticals industry based on its financial score.
2026-07-30 19:40:33
This article reports on a Form 4 filing for Biofrontera Inc. related to July 29th. It is a brief announcement without further details, typical of financial news sites reporting on regulatory filings. The article also includes various market data and other news headlines from Investing.com.
2026-07-30 11:11:38
This article provides a valuation analysis of Biofrontera Inc (BFRI), stating its current valuation score is 9.06 and ranks 55 out of 155 in the Pharmaceuticals industry. It highlights the company's P/E ratio of -1.21 but notes that relevant data for P/B, P/S, and P/CF ratios have not been disclosed by the company.
